An interlaboratory quality control programme for the measurement of tuberculosis drugs

European Respiratory Journal

Volumn 46, Issue 1, 2015, Pages 268-271

  Aarnoutse, Rob E ^a,b   Sturkenboom, Marieke G G ^c   Robijns, Karen ^b   Harteveld, Anneke R ^b   Greijdanus, Ben ^c   Uges, Donald R A ^c   Touw, Daniel J ^b,c   Alffenaar, Jan Willem ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Dutch Foundation for Quality Assessment in Medical Laboratories   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PURITY; DRUG STABILITY; DRUG SURVEILLANCE PROGRAM; GOOD LABORATORY PRACTICE; HUMAN; LETTER; MEASUREMENT ACCURACY; MEASUREMENT ERROR; MEASUREMENT PRECISION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; DRUG ADMINISTRATION; IMMUNOASSAY; LABORATORY; QUALITY CONTROL; REPRODUCIBILITY; STANDARD; STANDARDS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; IMMUNOASSAY; ISONIAZID; LABORATORIES; PYRAZINAMIDE; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RIFAMPIN; TUBERCULOSIS;

EID: 84937439857     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00177014     Document Type: Letter

References (15)

1. Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1959.
2. Mehta JB, Shantaveerapa H, Byrd RPJr, et al. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120: 1520-1524.
3. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40: 1481-1491.
4. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48: 1685-1694.
5. Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208: 1464-1473.
6. Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 2013; 69: 1091-1101.
7. Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 2012; 55: 169-177.
8. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74: 839-854.
9. Srivastava S, Peloquin CA, Sotgiu G, et al. Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Eur Respir J 2013; 42: 1449-1453.
10. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63.
11. Clinical Laboratory and Standards Institute. Using Proficiency Testing to Improve the Clinical Laboratory; Approved Guideline. 2nd Edn. Wayne, Clinical Laboratory and Standards Institute, 2007.
12. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother 2002; 46: 884-886.
13. Brüggemann RJ, Touw DJ, Aarnoutse RE, et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009; 53: 303-305.
14. Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011; 38: 888-894.
15. Sotgiu G, Centis R, D'Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J 2012; 40: 1430-1442.